Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug